miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD

Fangdong Lu; Huaping Gong; Linhai Duan; Yuan Yan; Long Chen; Pei Peng; Qiaoan Zhang; Wenrong Song; Jia Li

doi:10.1515/med-2023-0873

miR-29 regulates metabolism by inhibiting JNK-1 expression in non-obese patients with type 2 diabetes mellitus and NAFLD

Open Med (Wars). 2023 Dec 6;18(1):20230873. doi: 10.1515/med-2023-0873. eCollection 2023.

Authors

Fangdong Lu¹, Huaping Gong², Linhai Duan², Yuan Yan², Long Chen², Pei Peng³, Qiaoan Zhang³, Wenrong Song⁴, Jia Li⁴

Affiliations

¹ Wuhan University of Science and Technology, Wuhan 430065, China.
² Endocrinology Department, Hanchuan People's Hospital, Hanchuan 431600, China.
³ Clinical Laboratory Department, Hanchuan People's Hospital, Hanchuan 431600, China.
⁴ Endocrinology Department, Hanchuan People's Hospital, No. 1 People's Avenue, Hanchuan 431600, China.

Abstract

Previous studies have shown that microRNAs (miRNAs) are involved in the regulation of a variety of metabolic diseases, which related to some important signal pathways. Our aim was to explore the possible mechanism of miRNAs by revealing the differential expression of serum miRNAs in different BMI of type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). We found that miR-29 decreased liver aminotransferase gamma-GGT and uric acid levels by inhibiting the expression of JNK-1 in non-obese T2DM patients with NAFLD, and down-regulated the expression of atherosclerosis-related factor lipoprotein phospholipase A2 (Lp-PLA2). Combined with bioinformatics analysis, we speculate that this may be mediated by the AMPK signaling. These findings suggest that miR-29 may be a potential targeted therapeutic strategy in T2DM patients with NAFLD.

Keywords: AMPK signaling; JNK-1; NAFLD; diabetes mellitus; miR-29.